Prelude Therapeutics annual net profit margin
2024
2025
Prelude Therapeutics Net Profit Margin Growth & History (PRLD)
Prelude Therapeutics's net profit margin was −819.59% for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −819.59% | +997.17 pp |
| 2024 | 2024-12-31 | −1,816.76% | — |
Prelude Therapeutics quarterly net profit margin
Q3.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −244.06% | — |
| Q1 2026 | 2026-03-31 | −226.75% | — |
| Q4 2025 | 2025-12-31 | −291.79% | — |
| Q3 2025 | 2025-09-30 | −303.46% | +772.24 pp |
| Q3 2024 | 2024-09-30 | −1,075.70% | — |
Prelude Therapeutics net profit margin trends
Between the periods ended 2024-12-31 and 2025-12-31, Prelude Therapeutics's net profit margin increased from −1,816.76% to −819.59%, a change of +997.17 percentage points. The latest reported quarter, Q2 2026, shows −244.06%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...